Evidence map›Paper›PMID 35025014›Full record

ArticleInternational journal of clinical oncology2022

Hormone replacement therapy in relation to the risk of colorectal cancer in women by BMI: a multicentre study with propensity score matching.

Lingkai Xu, Lin Li, Dongkui Xu, Junlan Qiu, Qingting Feng, Tao Wen, Shun Lu, Fang Meng, Xiaochen Shu

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Lingkai Xu *Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, 215123, China.
Lin Li *Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, 215123, China.
Dongkui Xu *VIP Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Junlan Qiu *Department of Oncology and Hematology, the Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou, 215153, China.
Qingting FengDepartment of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, 215123, China.
Tao WenMedical Research Centre, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
Shun LuDepartment of Radiation Oncology, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, Chengdu, 610041, China.
Fang MengCentre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Xiaochen ShuDepartment of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, 215123, China. xcshu@suda.edu.cn.ORCID http://orcid.org/0000-0002-4933-5851
Soochow University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNCapital Medical University · CNSuzhou University of Science and Technology · CNUniversity of Electronic Science and Technology of China · CN

Funding

Scientific Research Foundation for Talented Scholars in Soochow University Q413900215
6 · The paper itself

Abstract

backgroundEpidemiological evidence about hormone replacement therapy and colorectal carcinogenesis by demographic and clinical traits remains unclear. We aimed to assess this postulated association in a large multicentre study and further explore the modification effect by BMI and others.

methodsWe retrospectively collected records of women diagnosed with colorectal cancer (CRC) at the age of 50 years and older during 2014-2017 and their HRT dispensing prior to CRC diagnosis in three tertiary hospitals in China. CRC cases were matched with controls at a ratio of 1:3 using nearest neighbour propensity scores matching to better control for the remaining imbalance between groups, which generated a total of 824 cases with 2472 controls.

resultsOur study confirmed the inversed association between colorectal cancer risk and hormone replacement therapy (OR, 0.62; 95% CI, 0.54-0.75), which was more prominent among women having multiple HRT dispenses (OR, 0.60; 95% CI, 0.52-0.76). Furthermore, significant associations were consistently observed for the short-term (OR, 0.69; 95% CI, 0.57-0.88), middle-term (OR, 0.51; 95% CI, 0.41-0.66), and long-term HRT users (OR, 0.70; 95% CI, 0.43-0.90). Estrogen-related regimen reduced CRC risk more than progestogen-only. We, for the first time, found that the modifying effect of BMI on HRT use and CRC risk was in different ways when BMI was categorized by a medium level of 27.

conclusionOur findings mainly suggest that there might be a different mechanism for the reversed association between HRT and colorectal tumorigenesis by BMI level, providing thoughts on clinical treatment of CRC.

Indexed as

Colorectal NeoplasmsBody Mass IndexEstrogen Replacement TherapyFemaleHormone Replacement TherapyHumansMiddle AgedPropensity ScoreRetrospective StudiesRisk FactorsBMIColorectal cancerEffect modificationHormone replacement therapy

Identifiers

PMID35025014
OpenAlexW4205713182

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.